• Blood Cancer Research Partnership

    Clinical Trials

    Open to Enrollment

    CTEP: 9204/DFCI 12-537: A Phase I/Ib Study of Ipilimumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

    Participating Sites:

    TH-CR-408/DFCI 11-425: A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

    Participating Sites:

    Enrolling Soon/In-Development

    A Multicenter Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies

    A Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients with Hematologic Malignancies

    A Prospective, Longitudinal, Observational Study in Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome

    A Phase II study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms